Literature DB >> 16600896

The greater than twofold cost of integration for retroviruses.

David C Krakauer1, Akira Sasaki.   

Abstract

Sexual reproduction, typically conceived of as a puzzling feature of eukaryotes, has posed an extraordinary evolutionary challenge in terms of the twofold replicative advantage of asexual over sexual organisms. Here we show mathematically that a greater than twofold cost is paid by retroviruses such as HIV during reverse transcription. For a retrovirus, replication is achieved through RNA reverse transcription and the effectively linear growth processes of DNA transcription during gene expression. Retroviruses are unique among viruses in that they show an alternation of generations between a diploid free living phase and a haploid integrated phase. Retroviruses engage in extensive recombination during the synthesis of the haploid DNA provirus. Whereas reverse transcription generates large amounts of sequence variation, DNA transcription is a high-fidelity process. Retroviruses come under strong selection pressures from immune systems to generate escape mutants, and reverse transcription into the haploid DNA phase serves to generate diversity followed by a phase of transcriptional clonal expansion during the restoration of diploidy from a stable, long lived, DNA encoded provirus.

Entities:  

Mesh:

Year:  2006        PMID: 16600896      PMCID: PMC1560259          DOI: 10.1098/rspb.2005.3322

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  19 in total

1.  Error catastrophe and antiviral strategy.

Authors:  Manfred Eigen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Recombination in HIV and the evolution of drug resistance: for better or for worse?

Authors:  Michael T Bretscher; Christian L Althaus; Viktor Müller; Sebastian Bonhoeffer
Journal:  Bioessays       Date:  2004-02       Impact factor: 4.345

3.  Levels of selection in positive-strand virus dynamics.

Authors:  D C Krakauer; N L Komarova
Journal:  J Evol Biol       Date:  2003-01       Impact factor: 2.411

4.  Optimizing within-host viral fitness: infected cell lifespan and virion production rate.

Authors:  Michael A Gilchrist; Daniel Coombs; A S Alan S Perelson
Journal:  J Theor Biol       Date:  2004-07-21       Impact factor: 2.691

5.  Co-infection weakens selection against epistatic mutations in RNA viruses.

Authors:  Rémy Froissart; Claus O Wilke; Rebecca Montville; Susanna K Remold; Lin Chao; Paul E Turner
Journal:  Genetics       Date:  2004-09       Impact factor: 4.562

Review 6.  RNA recombination in animal and plant viruses.

Authors:  M M Lai
Journal:  Microbiol Rev       Date:  1992-03

7.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

8.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

Review 9.  Escape of human immunodeficiency virus from immune control.

Authors:  A J McMichael; R E Phillips
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

10.  Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies.

Authors:  M A Ostrowski; D C Krakauer; Y Li; S J Justement; G Learn; L A Ehler; S K Stanley; M Nowak; A S Fauci
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

View more
  1 in total

1.  HIV-1 Genetic Variation Resulting in the Development of New Quasispecies Continues to Be Encountered in the Peripheral Blood of Well-Suppressed Patients.

Authors:  Will Dampier; Michael R Nonnemacher; Joshua Mell; Joshua Earl; Garth D Ehrlich; Vanessa Pirrone; Benjamas Aiamkitsumrit; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Jeffrey M Jacobson; Brian Wigdahl
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.